Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Drug interactions

Anaesthetists campaign for pholcodine cough medicines to become prescription-only products

The campaign follows fresh concerns about potentially fatal anaphylactic reactions.

Anaesthetists in Australia and New Zealand are campaigning for pholcodine-containing over-the-counter cough medicines to be made a prescription-only product

Source: Alamy

Muscle relaxant drugs that are given as part of a general anaesthetic could interact with pholcodine cough medicines, anaesthetists are warning

Anaesthetists in Australia and New Zealand are campaigning for pholcodine-containing cough medicines to become prescription-only products.

The call follows fresh concerns that the medicines may trigger a potentially fatal anaphylactic reaction to neuromuscular blocking drugs.

“Pholcodine has a structure that is similar to some of the muscle relaxant drugs that are given as part of a general anaesthetic,” explains Michael Rose, chairman of the Australian and New Zealand Anaesthetic Allergy Group (ANZAAG). “Some good research by Florvaag and Johansson[1] in Norway and Sweden identified that antibodies made by people to pholcodine may trigger anaphylaxis when the muscle relaxant with the similar structure is given. These reactions can be severe and can even result in brain damage or death.”

Follow–up research[2] found that after the products were withdrawn from sale in Norway in 2007, the number of fatal allergic reactions to muscle relaxants fell.

A recent review[3] into anaesthesia-related mortality in Australia and New Zealand between 2009 and 2011, published by the Australian and New Zealand College of Anaesthetists (ANZCA), found that seven deaths had been caused by an anaphylactic reaction to an anaesthetic.

Larry McNicol, chairman of the ANZCA mortality committee, says that although this number is small it has risen over the past three years, and five or six of the cases were linked to muscle relaxants.

Rose says that although there is evidence of an association between pholcodine cough medicines and the risk of a fatal anaphylactic reaction, proof of the link would require a clinical trial that “no one would be willing to fund”.

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) conducted a safety review of pholcodine-containing medicines in 2011 and decided that the products could remain on the market.

“The committee found no firm evidence to substantiate the hypothesis of cross sensitisation between pholcodine and neuromuscular blocking agents and a subsequent increased risk of anaphylactic reactions during surgery,” it said in 2011 following its review. “Pholcodine-containing medicines have been available for the treatment of non-productive cough in the EU for decades and existing data confirm a positive benefit-risk balance of these medicines.”

Rose warns that the countries in which pholcodine-containing cough medicines are freely available over the counter are likely to face similar safety concerns as those being observed in Australia and New Zealand.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20067520

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £133.00Buy now
  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £252.00Buy now
  • International Research in Healthcare

    International Research in Healthcare

    Guidance for students or researchers undertaking a multi-centre research project in health services, medicines use and professional practice.

    £38.00Buy now
  • Drugs in Use

    Drugs in Use

    Optimise drug therapy for your patients. These case studies help you bridge the gap between theoretical medicines knowledge and practical applications.

    £43.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.